Goserelin-d7
Goserelin-d7 (ICI 118630-d7) is deuterium labeled Goserelin. Goserelin (ICI 118630), a decapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH), functions as a GnRH agonist. Goserelin can be used for the research of breast cancer, epithelial ovarian cancer and prostate cancer[1][2].
Product Specifications
Product Name Alternative
ICI 118630-d7
UNSPSC
12352005
Target
Apoptosis; GnRH Receptor; Isotope-Labeled Compounds
Related Pathways
Apoptosis; GPCR/G Protein; Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Cancer; Endocrinology
Smiles
O=C([C@@H]1CCC(N1)=O)N[C@@H](CC2=CN=CN2)C(N[C@H](C(N[C@@H](CO)C(N[C@H](C(N[C@H](COC(C)(C)C)C(N[C@@H](CC(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])C(N[C@@H](CCCNC(N)=N)C(N3[C@@H](CCC3)C(NNC(N)=O)=O)=O)=O)=O)=O)CC4=CC=C(C=C4)O)=O)=O)CC5=CNC6=CC=CC=C56)=O
Molecular Formula
C59H77D7N18O14
Molecular Weight
1276.45
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Ning Zhang, et al. Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box O1 through the PI3K/AKT signaling pathway. Oncol Rep. 2018 Mar; 39 (3) : 1034–1042.|[3]Halle C F Moore, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372 (10) :923-32.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC682848-500 1x 500 µL
Fibronectin (Fn-3), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040149-500 1x 500 µL
CD106 / VCAM1 (1.4C3), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 